Elligo Health Research, an Austin, Texas-based integrated research organization (IRO), raised $20m in Series C funding.
The round was led by Piper Jaffray Merchant Banking, a division of Piper Jaffray, with participation from all lead Series A and B investors. In conjunction with the funding, Tom Schnettler, managing director at Piper Jaffray Merchant Banking, joined Elligo’s board.
The company intends to use the funds to expand its business reach.
Led by John Potthoff, PhD, CEO, Elligo Health Research is an integrated research organization (IRO), which accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using its clinical technology and a direct approach.
The company combines clinical experts with research infrastructure, creating a clinical trial solution that aims to ensure that all patients have access to clinical trials as a care option by maintaining the integrity of patient / physician relationship, and building global communities of research leveraging electronic health records.